Gastrointestinal Disorders

 
AbbVie's Risankizumab (Skyrizi) Approved to Treat Moderately to Severely Active Crohn Disease
June 28, 2022

The new approval for risankizumab makes it the only interleukin-23 inhibitor for moderately to severely active Crohn disease, according to AbbVie.

FDA Approved Dupilumab as the First Treatment for Eosinophilic Esophagitis
May 23, 2022

Dupilumab is approved for the treatment of eosinophilic esophagitis in patients aged ≥12 years weighing at least 40 kgs.

Study: One-fifth of Patients with Cirrhosis Prescribed Opioids During Clinic Visits
November 17, 2021

In a new study of patients with cirrhosis, over two-thirds of outpatient clinic visits that included an opioid prescription were with primary care physicians.

CDI-specific Follow-up Visits Rare among Patients Hospitalized for Recurrence
September 30, 2021

IDWeek 2021: A new study found that only 16% of patients with CDI rehospitalized for recurrent infection had been seen in follow-up 30 days after original discharge.

IDWeek 2021: C diff Clinical Outcomes Unchanged after 2017 IDSA Guideline Update
September 29, 2021

IDWeek 2021: Use of vancomycin vs metronidazole increased after the 2017 IDSA recommendation but CDI recurrence rates increased slightly, investigators report.

H Pylori Independently Associated with Carotid Plaque Formation, Investigators Find
September 27, 2021

Helicobacter pylori infection in early-middle-aged adults was associated with higher BMI, triglyceride levels, carotid plaque formation, and carotid intima-media thickness.

Seen in the ED: Hematochezia in a 1-year-old Girl
September 16, 2021

Intermittent pain causing the child to cry and an episode of bright red rectal bleeding are described by the mother. Review labs and imaging: What's your diagnosis?

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides Difficile Infection
September 02, 2021

The 2021 American College of Gastroenterology guidelines on management of C. difficile reflect an expanding body of evidence for preventing, diagnosing, and treating the dangerous infection.

Investigational Microbiota-based Therapy Bests Placebo to Reduce Recurrence of C. difficile Infection
September 02, 2021

The investigational, live biotherapeutic demonstrated superior efficacy vs placebo in reduction of recurrent Clostridioides difficile infection in ~100 patients at 8-week follow-up.

How to Help Patients Refine a Concept of Gut Health: Two Perspectives, One View
July 16, 2021

Patients interested in optimizing their own gut health have typically tried several approaches before they ask a clinician for help. Two specialists offer seasoned guidance on what helps most.